The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.